Patients with BRCA1 deficient cancers are also candidates for treatment with Poly (ADP-ribose) polymerase (PARP)-inhibitors, thus BRCA1 variant interpretation status is extremely important for treatment decisions [36–41]. Here, BRCA1 is linked to cancer.